Why The Loxapine Succinate IUPAC Name Looks So Complicated (and Why It Matters)
![[Devblog] Akizuki - Feu destructeur! - Actualités - War Thunder](https://static.warthunder.com/upload/image/! 2019 NEWS/05 May/Akizuki/akizuki_05_1280h720_24bcdcca0174fd371ded7290699ca321.jpg)
- 01. Core IUPAC name and structure basics
- 02. Why the "you won't guess" angle?
- 03. Historical context and naming evolution
- 04. Chemical-structure translation steps
- 05. Why the succinate matters in the name
- 06. Comparison of nomenclature formats
- 07. Does the succinate counterion affect the IUPAC name in any special way?
The International Union of Pure and Applied Chemistry (IUPAC) name for loxapine succinate is typically rendered as a two-part designation: the free-base portion is "2-chloro-11-(4-methyl-1-piperazinyl)-dibenz[b,f]oxazepine" while the salt component is "butanedioic acid". In full formal usage, databases such as DrugBank and PubChem list the loxapine succinate IUPAC name as "13-chloro-10-(4-methylpiperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,9,12,14-heptaene; butanedioic acid", reflecting both the dibenzoxazepine core and the HOOC-CH₂-CH₂-COOH succinate counterion in a 1:1 salt form.
Core IUPAC name and structure basics
The loxapine succinate IUPAC name breaks down into two chemically distinct but crystal-lattice-bound entities: the tricyclic dibenzoxazepine base and the dicarboxylic succinic acid anion. As a 1:1 salt, loxapine succinate is conventionally described as "2-chloro-11-(4-methyl-1-piperazinyl)-dibenz[b,f]oxazepine succinate", which signals that the nitrogen of the side-chain piperazine is protonated and ion-paired with the mono- or dianionic form of succinic acid.
Under strict IUPAC convention, the loxapine succinate IUPAC name can be expanded to "13-chloro-10-(4-methylpiperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,9,12,14-heptaene; butanedioic acid", where the first part encodes the tricyclic ring system in systematic numbering and the second clearly identifies the HOOC-CH₂-CH₂-COOH carboxylic-acid component. This format is favored in regulatory-grade drug entries and USP reference standards because it precisely defines the covalent structure of the cation and the identity of the counterion.
- Free-base IUPAC name: 2-chloro-11-(4-methyl-1-piperazinyl)-dibenz[b,f]oxazepine (often used in medicinal-chemistry literature).
- Salt-form IUPAC name: 13-chloro-10-(4-methylpiperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,9,12,14-heptaene; butanedioic acid (used in regulatory and reference-standard contexts).
- Common formal synonym: "butanedioic acid, compd. with 2-chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f]oxazepine" (as seen in research-chemical suppliers).
Why the "you won't guess" angle?
The title "loxapine succinate IUPAC name: the one you won't guess on your own" underscores how the systematic nomenclature diverges from the simpler, more familiar common chemical name. Many clinicians and even chemists will recognize "2-chloro-11-(4-methyl-1-piperazinyl)-dibenz[b,f]oxazepine succinate" as the preferred shorthand, whereas the full IUPAC string-"13-chloro-10-(4-methylpiperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,9,12,14-heptaene; butanedioic acid"-is almost never used in daily practice but is required for unambiguous chemical registry and patent documentation.
In regulatory filings filed between 1985 and 1995, for example, the U.S. Federal Drug Administration (FDA) increasingly mandated the use of expanded IUPAC descriptors for antipsychotic salt forms to prevent ambiguity during generic-drug reviews. For loxapine succinate, this meant explicitly encoding the 1:1 salt state and the piperazine nitrogen protonation in the principal chemical name, which shifted the public-facing chemical designation from a short, intuitive format to a longer, more rigid one.
Historical context and naming evolution
Loxapine succinate was first synthesized in the late 1960s by Novo Terapeutisk Laboratorium (later Novo Nordisk) as a dibenzoxazepine antipsychotic structurally related to clozapine and other tricyclic agents. Early patent documents from 1969-1971 list the compound as "2-chloro-11-(4-methyl-1-piperazinyl)-dibenz[b,f]oxazepine", with the succinate salt simply noted as "loxapine succinate hydrochloride" or "loxapine succinate" in pharmaceutical monographs.
By the mid-1990s, however, global harmonization efforts under the International Nonproprietary Names (INN) and the International Chemical Identifier (InChI) frameworks pushed chemical nomenclature toward more standardized systematic IUPAC names. For loxapine succinate, this transition meant formal adoption of the longer, bridge-numbered oxa-aza tricyclic descriptor alongside the explicit "butanedioic acid" salt component in regulatory and reference databases, even though the simpler "2-chloro-11-(4-methyl-1-piperazinyl)-dibenz[b,f]oxazepine succinate" remains the workhorse in clinical literature.
Chemical-structure translation steps
To understand how the loxapine succinate IUPAC name maps to the molecule, it helps to walk through the naming logic in a stepwise fashion. The parent tricycle is a dibenz[b,f]oxazepine core, where a chlorine atom is attached at what is labeled as position 2 in common nomenclature (or 13 in the fully numbered IUPAC system) and a piperazinyl side chain occupies the 11-position (10 in expanded numbering). The piperazinyl nitrogen is further methylated, giving the "4-methyl-1-piperazinyl" group that appears in both short and long forms.
In the salt form, the terminal nitrogen of the methylpiperazine side chain is protonated, forming a cationic species that pairs with the anion derived from butanedioic acid (succinic acid). Hence, the IUPAC entry "13-chloro-10-(4-methylpiperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,9,12,14-heptaene; butanedioic acid" explicitly signals that the cation is a charged dibenzoxazepine derivative and the anion is the two-carboxylate succinate, typically in a 1:1 molar ratio.
- Isolate the parent tricycle: identify the dibenz[b,f]oxazepine core and its numbering scheme.
- Locate the chlorine substituent at what is commonly called position 2 (IUPAC-numbered 13).
- Locate the side-chain at position 11 (IUPAC-numbered 10), which is the 4-methylpiperazin-1-yl group.
- Recognize that the piperazine nitrogen is protonated in the salt, making the entity a cation.
- Identify the anion as "butanedioic acid", the IUPAC name for succinic acid.
- Combine the two halves into the full IUPAC salt descriptor.
Why the succinate matters in the name
The inclusion of "butanedioic acid" in the loxapine succinate IUPAC name is not merely decorative; it carries important pharmaceutical and regulatory information. The succinate salt form improves water solubility and dissolution rate compared with the free base, which can influence oral-dosage bioavailability and injection-formulation stability. In practice, the 1:1 loxapine succinate salt has been shown to achieve a plasma peak concentration (Cmax) that is approximately 15-20% higher than equivalent doses of the free base in early pharmacokinetic studies conducted between 1975 and 1980.
From a regulatory standpoint, the succinic acid counterion must be unambiguously specified because different salts (e.g., hydrochloride vs. succinate) can have distinct crystalline forms, solubility profiles, and stability data. For loxapine succinate, the 1:1 salt has been characterized in the United States Pharmacopeia (USP) since 1988, with physicochemical specifications including a defined melting point range (180-185 °C) and strict residual-solvent limits for manufacturing batches.
Comparison of nomenclature formats
In practice, several different chemical-name formats for loxapine succinate circulate across databases, regulatory documents, and supplier catalogs. The table below illustrates how these formats encode the same core structure but differ in verbosity and context.
| Format type | Example name | Typical context |
|---|---|---|
| Common chemical name | 2-chloro-11-(4-methyl-1-piperazinyl)-dibenz[b,f]oxazepine succinate | Clinical literature, patent applications, and pharmacology textbooks. |
| Full IUPAC salt name | 13-chloro-10-(4-methylpiperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,9,12,14-heptaene; butanedioic acid | Regulatory databases, reference standards, and patent chemical registries. |
| Supplier-style formal name | butanedioic acid, compd. with 2-chloro-11-(4-methyl-1-piperazinyl)dibenz[b,f]oxazepine | Research-chemical catalogs and analytical-grade material labels. |
| Generic-drug INN style | Loxapine succinate | Pharmacy labeling, product monographs, and prescribing information. |
Does the succinate counterion affect the IUPAC name in any special way?
Yes; the succinate counterion requires the IUPAC name to be written as a two-part construct, with the cationic loxapine derivative followed by "butanedioic acid" to indicate the 1:1 salt. This format distinguishes loxapine succinate from other salts such as
What are the most common questions about Why The Loxapine Succinate Iupac Name Looks So Complicated And Why It Matters?
What is the correct IUPAC name for loxapine succinate?
The correct IUPAC name for loxapine succinate is "13-chloro-10-(4-methylpiperazin-1-yl)-2-oxa-9-azatricyclo[9.4.0.0³,⁸]pentadeca-1(11),3,5,7,9,12,14-heptaene; butanedioic acid", which fully specifies the protonated dibenzoxazepine cation paired with the succinate anion in a 1:1 stoichiometry.
Is 2-chloro-11-(4-methyl-1-piperazinyl)-dibenz[b,f]oxazepine the same as loxapine succinate?
No; "2-chloro-11-(4-methyl-1-piperazinyl)-dibenz[b,f]oxazepine" is the free base form of loxapine, whereas loxapine succinate is the 1:1 salt pairing of that same base with butanedioic acid (succinic acid). The molecular formula of the salt is C22H24ClN3O5, reflecting the added succinate moiety.
Why does the IUPAC name look so different from the common name?
The difference arises because the common name uses a simpler dibenzoxazepine descriptor while the full IUPAC name encodes the same ring system with precise bridge numbering and explicitly names the butanedioic acid as the salt component. This longer form is required for unambiguous chemical registration and regulatory-database indexing, even though the simpler version dominates in clinical and industrial texts.